Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR) Head to Head Analysis

Entrada Therapeutics (NASDAQ:TRDA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Volatility & Risk

Entrada Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Valuation & Earnings

This table compares Entrada Therapeutics and X4 Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42 million	6.76	-$143.75 million	($3.96)	-1.11
X4 Pharmaceuticals	$35.11 million	9.15	-$79.20 million	($1.20)	-2.70

X4 Pharmaceuticals has higher revenue and earnings than Entrada Therapeutics. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Entrada Therapeutics and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Analyst Ratings

This is a breakdown of current ratings and target prices for Entrada Therapeutics and X4 Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	2	4	0	2.43
X4 Pharmaceuticals	1	1	4	0	2.50

Entrada Therapeutics currently has a consensus price target of $17.75, suggesting a potential upside of 302.49%. X4 Pharmaceuticals has a consensus price target of $11.25, suggesting a potential upside of 247.22%. Given Entrada Therapeutics’ higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than X4 Pharmaceuticals.

Insider & Institutional Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

X4 Pharmaceuticals beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.